This book provides an overview of critical components of cell signaling machinery and its role in epithelial morphogenesis, proliferation, invasions and angiogenesis in human cancer and discusses novel types of protein kinase pathways.

Nitric Oxide (NO) is a pleitropic, ubiquitous modulator of cellular functions. Aryl nitrite and glyceryl trinitrate, representative intravasadilators, were introduced as therapeutic agents more than a century ago for relief from acute attacks of angina. The vasodilator action is mediated by the release of NO following treatment. NO has important therapeutic applications in several diseases such as inflammatory diseases, erectile dysfunction, inflammation, pain and neural protective activity. However, the role of NO in cancer and its application in therapy has received little attention. This monograph will be the first to focus on studies that investigate the role of NO in tumor cell pathogenesis, growth, angiogenesis, response to cytotoxic therapies and NO translational applications in cancer therapy, alone or in conjunction with other therapies.

There are now compelling human epidemiological and animal experimental data that indicate the risk of developing adult-onset complex diseases and neurological disorders are influenced by persistent epigenetic adaptations in response to prenatal and early postnatal exposures to environmental factors. Epigenetics refers to heritable changes in gene function that occur without a change in the sequence of the DNA. The main components of the epigenetic code are DNA methylation, histone modifications, and non-coding RNAs. The epigenetic programs are established as stem cell differentiate during embryogenesis, and they are normally faithfully reproduced during mitosis. Moreover, they can also be maintained during meiosis, resulting in epigenetic transgenerational disease inheritance, and also potentially introducing phenotypic variation that is selected for in the evolution of new species. The objective of this two volumebook is to provide evidence that environmental exposures during early development can alter the risk of developing medical conditions, such as asthma, autism, cancer, cardiovascular disease, diabetes, obesity, and schizophrenia later in life by modifying the epigenome. Consequently, epigenetic research promises to markedly improve our ability to diagnosis, prevent, and treat the pathological conditions of humans; however, it also introduces unique legal and ethical issues. This volume highlights the correlation between environmental factors and complex diseases, such as autism, addiction, neurological diseases, diabetes, obesity and cancer. It concludes with a chapter on legal and ethical implications of epigenetics. "

This book explores in depth the relation between physical activity and cancer control, including primary prevention, coping with treatments, recovery after treatments, long-term survivorship, secondary prevention, and survival. The first part of the book presents the most recent research on the impact of physical activity in preventing a range of cancers. In the second part, the association between physical activity and cancer survivorship is addressed. The effects of physical activity on supportive care endpoints (e.g., quality of life, fatigue, physical functioning) and disease endpoints (e.g., biomarkers, recurrence, survival) are carefully analyzed. In addition, the determinants of physical activity in cancer survivors (e.g., medical, social cognitive, environmental) are discussed, and behavior change strategies for increasing physical activity in cancer survivors (e.g., counseling, print materials) are appraised. The final part of the book is devoted to further special topics, including the relation of physical activity to pediatric cancer survivorship and to palliative cancer care.

The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy."

Recent advances have contributed to our understanding of how a plant-based diet confers many health advantages and how substances from plants may be effective in the prevention of specific cancers. The Ninth Annual Research Conference of the American Institute for Cancer Research has focused on the latest developments in several categories of nutrients of wide contemporary interests. The conference sessions included such topics as the effects of soy, green tea, selenium, wine, grapes, and spices in cancer prevention. This conference was held in Washington, D.C. on September 2nd and 3rd, 1999, and was entitled Nutrition and Cancer Prevention: New Insights Into the Roles of Phytochemicals. The discussion program included a session that was devoted to the current status of herbal products in relation to cancer prevention, in recognition of the increasing attention that complementary and alternative medicine has been receiving from the scientific community as well as the general public. A separate presentation addressed the issue of nutritional supplements and cancer prevention.

Lung cancer is one of the biggest challenges in oncology today. The challenge is due to the recognition of the possibility of prevention in at least 70-80 % of all the cases and the extreme difficulties encountered in the treatment of this neoplasm. Despite the knowledge of prevention measures such as cessation of cigarette smoking the incidence continues to increase in many countries. The increase is particularly notable in females in the west ernized countries where the death rate in females in certain regions sur passes that of breast cancer. Furthermore, in many developing countries lung cancer is now being diagnosed with increasing frequency in both sexes and it is expected to be a major cause of death in those countries later in this century or the beginning of next century if the tobacco consumption will continue its rapid rise. With respect to therapy the 1970'es brought considerable progress in understanding of the clinical behaviour of lung cancer thereby establishing the importance of distinguishing between the major histologic types. Thera peutic advancement was particularly experienced in small cell carcinoma with the introduction of combination chemotherapy after this special dis ease entity among lung cancers was recognized as being a disseminated dis ease in almost all cases at the time of diagnosis. It was expected that the improvement in therapy would have continued in the early 1980'es, not only for small cell lung cancer but also for the other cell types."

Prostaglandins, Leukotrienes, and Cancer is a multi-volume series that will focus on an emerging area of cancer research. In 1968, R.H. Williams first reported that elevated prostaglandin levels are present in human medullary car- cinoma. Since that time, the concept that arachidonic acid metabolites may be in- volved in cancer has expanded to include every aspect of the disease from cell transformation through metastasis. Prostaglandins and leukotrienes are generic terms used to describe a family of bioactive lipids produced from unsaturated fatty acids (principally from arachidonic acid) via the cyclooxygenase and lipoxygenase pathways, respec- tively. Cyclooxygenase products consist of diverse products such as prosta- glandin Ez (PGEz), prostacyclin (PGIz) and thromboxane Az (TXAz), whereas lipoxygenase products consist of hydroperoxy fatty acids and mono-, di- and tri-hydroxy acids including leukotrienes. The precursor fatty acids for the cyclooxygenase and lipoxygenase pathways are present in cellular phospholipids. This finding established an important control point in their biosynthesis-the release of substrate. This occurs in response to numerous stimuli that act at the cell surface. Dr. Bengt Samuelsson's extensive study of the metabolism of pros- taglandins indicated that they are rapidly inactivated on a single pass through pulmonary circulation. Thus, they cannot act as circulating hormones and appear to be made on demand in or in the vicinity of target tissues leading to the concept that prostaglandins are local hormones or autocoids.

DNA tumor viruses have long been useful experimental models of carcinogenesis and have elucidated several important mechanisms of cell transformation. Re search in recent years has shown that human tumors have a multifactorial nature and that some DNA tumor viruses may playa key role in their etiology. The aim of this book is to assess our knowledge of DNA tumor viruses by reviewing animal models, mechanisms of transformation, association with human tumors, and possi bilities of prevention and control by vaccination. Animal models of tumor virology have contributed significantly to our under standing of the epidemiology and pathogenesis of virus-induced tumors. Bovine papillomaviruses induce papillomas in the intestine of cattle. The papillomas undergo a transition to carcinomas in cows feeding on bracken fern, which pro duces a toxin with radiomimetic and immunosuppressive functions. This example of cooperation between a virus and chemical carcinogens parallels the cooperative role of human papillomaviruses (HPVs) and herpes simplex virus type 2 (HSV-2) with environmental carcinogens in the pathogenesis of cervical cancer. Likewise, hepatocarcinomas appearing in woodchucks chronically infected by woodchuck hepatitis virus (WIN) provide strong support for the relationship between hepatitis B virus (HBV) infection and human hepatocellular carcinoma. Also, the fact that WIN DNA integrates closely to cellular oncogenes suggests a possible molecular mechanism for the tumorigenesis induced by HBV."

Breast Care: A Clinical Guidebook for Women's Primary Health Care Providers presents the expertise and protocols of the renowned Breast Diagnostic Center at USC School of Medicine's Department of Obstetrics and Gynecology. A user-friendly reference for the primary care physician, this book details the management of both benign and malignant breast diseases. Topics include: * the clinical examination and instruction for self-exam * mammography for both screening and diagnosis, management of the abnormal mammogram * lactation and breast feeding * diagnosis and treatment of lumps, cysts, fibroadenomas * fine-needle aspiration and ultrasound guided tissue core needle biopsy * evaluation and management of mastalgia * menstrual and hormonal therapy effects on the breast * the cosmetically treated breast * guidelines for follow-up and surveillance An important section on consultation and referrals reviews the roles of the radiologist, oncologist, and surgeon and provides the primary care physician with the information necessary to counsel the patient on the myriad aspects of multidisciplinary treatment planning. The text includes more than 100 illustrations and algorithms -- with 16 in color -- as well as "Practice Guides" which organize the key practice points, signs, and symptoms. This is a must-have handbook for all providers of health care to women.

The dramatic decrease in the incidence of stomach cancer in industrialized countries during the past 50 years, which is yet to be fully explained, and the observation that carcinogenesis in laboratory animals can be inhibited by antioxidants, retinoids, and caloric restriction, among other influences, challenge us to press on in the search for practical means to prevent cancer. It is in relation to this goal that the studies summarized in this book have special significance. This book is based on the invited and contributed papers presented at the Third Internationai Conference on Anticarcinogenesis and Radiation Protection, held on October 15-21, 1989, in Dubrovnik, Yugoslavia. They cover a broad range of investigations into the mechanisms and inhibition of carcinogenesis. In keeping with recent advances in our understanding of the importance of oncogenes and tumor-suppressor genes in carcinogenesis, many of the reports focus on mutations and related changes at the level of DNA. At the same time, however, other reports deal with nutritional, immunological, endocrinological, and epidemiological aspects. In all, the various reports address carcinogenesis and its inhibition at virtually every level of biological organization. Included in this compendium are timely reviews of diverse and promising research strategies for cancer prevention, as pursued by investigators in different parts of the world. The Organizers of the Conference are grateful to the many scientists who have contributed to the volume, as well as to the sponsors of the Conference, without whose generous support this book would not have been possible.

Japan has long been a leader of research into the carcinogenesis, pathology, diagnosis, and treatment of gastric carcinoma, which is still the second leading cause of cancer death worldwide. Distinguished experts in the field collaborated in creating this groundbreaking work, providing a comprehensive view of gastric cancer. This book encourages further development of gastric cancer research and its clinical application. Topics include all aspects of gastric carcinoma, such as the history of clinical and experimental gastric cancer research; updated issues of molecular and pathological research on gastric carcinogenesis; multidisciplinary methods in diagnosis, treatment, and chemotherapy; and perspectives in minimally invasive surgery. Color figures of histological specimens and other clinical features assist readers in readily understanding the textual descriptions, making this volume a valuable source for clinicians and researchers alike.

In the age of the World Wide Web, informed patients continue to surprise oncologists with detailed questions about popular tumor therapies. Although minimally invasive tumor therapies (MITT) have become daily clinical practice for palliative treatment of liver tumors, the acceptance of these palliative modalities still varies enormously. In addition, promising results have been published for in situ ablation of lung metastases, bone tumors, and renal cell carcinoma. This book gives an up-to-date overview of the popular techniques and clinical results of MITT, with a clarification of the actual indications including the size, tumor entities, and clinical benefits. Moreover, the book focuses on the prospectives and limitations of imaging methods - ultrasound, computed tomography, and magnetic resonance imaging - used for MITT.

Aberrant expression and function of microRNAs (miRNAs) in cancer have added a new layer of complexity to the understanding of development and progression of the disease state. It has been demonstrated that miRNAs have a crucial function in oncogenesis by regulating cell proliferation and apoptosis as oncogenes or tumor suppressors. The expression signatures of miRNAs provide exciting opportunities in the diagnosis, prognosis and therapy of cancer. Since miRNAs can function as either oncogenes or tumor suppressor genes in oncogenesis, the potential of using these small RNAs as therapeutic targets opens up new opportunities for cancer therapy by either inhibiting or augmenting their activity.

This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenstroem's macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.

The study of immunology encompasses a vast and ever-growing body of information that in some way or other incorporates most areas of medical biological research. As the body of information in the medical sciences continues to increase its rate of expansion, one of the greatest challenges to investigators will be to integrate this information in a manner that is intellectually fruitful and productive. Considering the intended scope of this text, we could not pretend to have gone too far toward achieving such an integration--and considering the pace of change, in its very best form a measured approximation of such lofty goals might be the most we could hope for. Nevertheless, in these pages we have sought to produce a collection of information that is at once concise and up-to-date regarding areas where important developments are impacting on the way we understand the vertebrate immune system. In addition, although the information is geared toward advanced study, we have discussed some basic elements and concepts that we hope make the text a useful resource for both the immunologist and the nonspecialist. The intention is to provide the researcher, clinician, or advanced undergraduate student with a brief ov- view of specific components of the immune system, and to provide a place from which to begin further detailed study if necessary. To this end, we made every effort to supply extensive referencing--although limitations in space prevented exhaustive or complete referencing in some cases.

Pituitary adenomas account for 10-15% of all intracranial tumors and they frequently impair fertility. The development of medical and surgical therapy for such tumors has turned pregnancy into a reality for women harboring pituitary adenomas. However, gestation risks for both mother and fetus are still of concern for endocrinologists, gynecologists and pediatricians. This book intends to update knowledge on this topic, mainly regarding fertility restoration as well as gestational and post gestational management of patients with pituitary tumors.

The current age of clinical medicine is witnessing biotechnological innovation at an unprecedented pace. As a result, the recently popularized clinical practice guidelines (CPG), as a tool to assist clinical decision-making, have been struggling to keep up. Thyroid Cancer: From Emergent Biotechnology to Clinical Practice Guidelines rides the wave of medical innovation, analyzing current and future CPG, and providing an up-to-date and comprehensive treatise on thyroid cancer, its diagnosis, and treatment.

A synthesis of ideas by prominent world experts in the field of thyroid cancer research and clinical practice, Thyroid Cancer covers:

• Technologically-advanced diagnostic procedures and therapeutic interventions
• Diagnostic techniques employed in the detection and follow-up of thyroid cancer including ultrasound, needle aspiration techniques, CT, PET, PET-CT, and MRI
• Basic principles of systems biology, molecular and translational medicine, CPG development, and risk stratification for thyroid cancer
• How CPG contain knowledge gaps and produce uncertainty
• Advances in the field, including new surgical techniques, molecular targeted therapies, external beam radiation therapy, and chemotherapy

A comprehensive, scientific description of current and future diagnostic and therapeutic modalities for the management of thyroid cancer, this treatise is an indispensible reference for both the specialist and referring physician.

The fight against breast cancer is expected to be effectively stimulated by interdisciplinary approaches and cross-fertilization between laboratory and clinical research findings. Of major importance are therefore meetings promoting fast transfer to clinical applications of findings by basic scientists. The present volume, reporting the proceedings of the 1991 Biennial Conference of the International Association for Breast Cancer Research, hopes to achieve this goal by presenting the most recent observations in the laboratory and their possible applications for diagnostic evaluations and clinical treatments. The sections of the book focus first on the oncogenes more likely involved in mammary tumorigenesis and on the polypeptide factors and steroid hormones affecting proliferation and possibly inducing carcinogenesis in breast epithelium. A section is devoted to the epidemiological studies and to the identification of risk factors, a way to select populations at higher risk and, possibly, to help in preventing the disease. Special emphasis is given to the establishment of diagnostic criteria and to the selection of prognostic factors, which must support an effective therapeutic planning. It is our hope that this volume, a timely update of the most recent advances in specific fields presented by basic scientists, pathologists and clinicians will stimulate new insights and progresses leading ultimately to the control of breast cancer.

The culmination of 30 years of research and experience in T-cell-based cancer, this book highlights and evaluates new treatments that harness the power of the T cell to attack and kill all cancer cells in our bodies. It describes how the T cell immune system can be manipulated and redirected to kill resistant cancer cells by understanding and influencing the interaction of many different immune cells in the body. Citing current experimental trials, it examines the role and pathology of T-cells and suggests additional experimental approaches to the problem.

Vast therapeutic applications of the following specific stem cells in disease and tissue injury are discussed: embryonic stem cells, induced pluripotent stem cells, human hair follicle stem cells, bone marrow-derived human mesenchymal stem cells, adipose-derived stem cells, periodontal/progenitor cells, cancer stem cells, and breast cancer stem cells. Because human embryonic stem cells possess the potential to produce unlimited quantities of any human cell type, considerable focus is placed on this type of stem cells in this volume. The role of cancer stem cells, specifically in breast cancer is explained. Transplantation of mesenchymal stem cells to aid the injured brain is included. Immune recovery after stem cells transplantation in severe combined immunodeficiency patients is described. The role of mesenchymal stem cells in enhancing the growth and metastasis of colon cancer is discussed. Clinical application of human follicle stem cells is presented. Treatment of malignant gliomas using genetically-modified neural stem cells as a marker is discussed. The impact of cancer stem cell hypothesis on designing new cancer therapies is explained. In the field of regenerative medicine, the use of stem cells in the repair of the central nervous system, tendon injury, and as a cardiac regenerative medicine is described. The role of DNA methylation in maintaining stemness induced pluripotent stem cells from human extraembryonic amnion cells is discussed. Insights on the understanding of molecular pathways involved in tumor biology are explained, which lead to the development of effective drugs. Information on pathways, such as hedgehog, facilitates targeted therapies in cancer.